$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Enhancers are cis-regulatory DNA elements that control target gene transcription by organizing chromatin looping and recruiting the transcriptional machinery1,2,3. Their tissue-specific activity enables precise regulation during development and lineage commitment4,5,6,7,8. Active enhancers show characteristic chromatin features such as H3K4me1 (histone H3 Lysine 4 mono-methylation) and H3K27ac (histone H3 Lysine 27 acetylation) and are usually found in DNase I hypersensitive regions that mark open chromatin9,10,11,12. These features enable transcription factors and RNA polymerase II to access the DNA, initiating nascent transcription at enhancer loci13,14,15,16.
This sequential biological process produces enhancer-derived transcripts, called eRNAs, which are bidirectional, noncoding, and typically non-polyadenylated RNAs13,14,15,16. eRNAs serve as markers of enhancer activity and function as effectors in their own right16,17,18,19,20,21,22,23,24. They promote productive elongation by releasing Negative Elongation Factor (NELF) from paused RNA polymerase II16,19, and help stabilize enhancer-promoter loops17,18,20. They also support the formation of transcriptional condensates, potentially via m6A (N6-Methyladenosine) modification21,22,23.
Still, the function of intragenic enhancer transcription, initiated from regulatory elements within gene bodies, remains controversial. Some studies report that eRNAs from intragenic enhancers augment host gene expression25, potentially by promoting NELF release and stimulus-dependent productive elongation26,27. In contrast, other work suggests that this transcription can impede host genes via RNA polymerase II collisions or transcriptional interference, leading to attenuation or premature termination28,29. These conflicting observations, together with the dual role of eRNAs as markers and regulators, highlight the need for careful quantification and functional dissection. Yet, measuring intragenic eRNAs is difficult because they often overlap sense-strand host transcripts13,25,26,30. The challenge is amplified when enhancers reside in regions with nested genes or overlapping transcription on both strands, which obscures enhancer-specific signals.
To overcome these challenges, we developed a bioinformatics pipeline to detect, quantify, and visualize enhancer-associated transcripts, with a particular focus on intragenic regions. The pipeline integrates the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq), Chromatin Immunoprecipitation Sequencing (ChIP-seq), Global Run-on Sequencing (GRO-seq), and genomic annotations to achieve enhancer-level resolution even in complex genomic contexts.
The pipeline comprises four major steps: (i) preprocessing, alignment, peak calling, and signal generation31; (ii) enhancer identification using chromatin features; (iii) strand orientation assignment, particularly within gene bodies; and (iv) quantification and visualization of nascent enhancer transcripts. This framework is particularly useful for systems with high-resolution sequencing data, such as the mouse embryonic stem cells analyzed in this study, and it can be extended to other organisms when suitable datasets are available. By enabling enhancer-specific quantification where existing pipelines fall short, this workflow offers a practical tool for benchmarking and studying intragenic eRNA transcription across diverse genomic contexts.